NCT04644770 2026-03-13A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate CancerJanssen Research & Development, LLCPhase 1 Active not recruiting144 enrolled